Phosplatin Therapeutics Inc., a US-based clinical stage pharmaceutical company focused on oncology therapeutics, announced on Thursday that it has added Lorenzo Galluzzi, PhD to the company's Scientific Advisory Board.

Dr Galluzzi heads the Galluzzi Lab at Weill Cornell Medical College in New York. He has experience in oncology research, teaching at top universities in the US and Europe. He serves in multiple professorial roles, including at Weill Cornell Medical College as head of the Galluzzi Lab and assistant professor of Cell Biology in Radiation Oncology, and at Yale School of Medicine as assistant professor adjunct at the Department of Dermatology, associate director of the European Academy for Tumor Immunology, and founding member of the European Research Institute for Integrated Cellular Pathology.

Phosplatin president and chief executive officer Robert Fallon, said, 'We are excited for this new phase in our relationship with Dr. Galluzzi, who is world renowned for his research in immunogenic cell death in the field of oncology. Dr Galluzzi's research has been instrumental in PT-112's development trajectory and his expertise will complement our Scientific Advisory Board as we advance PT-112 in clinical trials for treating multiple cancer types, including lung and prostate cancers, and the rare disease thymoma.'